col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


50 Results       Page 1

 [1] 
Wiley: British Journal of Pharmacology
  original article Date Title Authors   Max. 6 Authors
1 [GO] 2024―Feb―15 MicroRNA-guided drug discovery for mitigating persistent pulmonary complications in critical COVID-19 survivors: A longitudinal pilot study María C. García-Hidalgo, Iván D. Benítez, Manel Perez-Pons, Marta Molinero, Thalía Belmonte, Carlos Rodríguez-Muñoz, María Aguilà, Sally Santisteve, Gerard Torres, Anna Moncusí-Moix, Clara Gort-Paniello, Rafael Peláez, Ignacio M. Larráyoz, Jesús Caballero, Carme Barberà, Estefania Nova-Lamperti, Antoni Torres, Jessica González, Ferran Barbé, David de Gonzalo-Calvo
2 [GO] 2023―Oct―13 Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure Rolf Schreckenberg, Nadine Woitasky, Nadja Itani, Laureen Czech, Péter Ferdinandy, Rainer Schulz
3 [GO] 2023―Jul―05 Cathepsins and SARS-CoV-2 infection: from pathogenic factors to potential therapeutic targets Shuxuan Zhao, Muzhou Jiang, Hong Qing, Junjun Ni
4 [GO] 2023―Jun―01 The severity of SARS-CoV-2 infection in K18-hACE2 mice is attenuated by a novel steroid-derivative in a gender-specific manner Sachin A. Gupte, Chandra Shekhar Bakshi, Emma Blackham, Gerald E. Duhamel, Allan Jordan, Padmini Salgame, Melinee D’silva, Mohammad Y. Khan, Jerry Nadler, Rakhee Gupte
5 [GO] 2023―Feb―27 Veklury® (remdesivir) formulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether-β-cyclodextrin content Tamas Kovacs, Kitti Kurtan, Zoltan Varga, Peter Nagy, Gyorgy Panyi, Florina Zakany
6 [GO] 2022―Dec―17 Neuraminidase is a host-directed approach to regulate neutrophil responses in sepsis and COVID-19 Rodrigo de Oliveira Formiga, Flávia C. Amaral, Camila F. Souza, Daniel A. G. B. Mendes, Carlos W. S. Wanderley, Cristina B. Lorenzini, Adara A. Santos, Juliana Antônia, Lucas F. Faria, Caio C. Natale, Nicholas M. Paula, Priscila C. S. Silva, Fernanda R. Fonseca, Luan Aires, Nicoli Heck, Márick R. Starick, Celso M. Queiroz-Junior, Felipe R. S. Santos, Filipe R. O. de Souza, Vivian V. Costa, Shana P. C. Barroso, Alexandre Morrot, Johan Van Weyenbergh, Regina Sordi, Frederico Alisson-Silva, Fernando Q. Cunha, Edroaldo L. Rocha, Sylvie Chollet-Martin, Maria Margarita Hurtado-Nedelec, Clémence Martin, Pierre-Régis Burgel, Daniel S. Mansur, Rosemeri Maurici, Matthew S. Macauley, André Báfica, Véronique Witko-Sarsat, Fernando Spiller
7 [GO] 2022―Dec―09 Hypothesis: Efficacy of early treatments with some NSAIDs in COVID-19: Might it also depend on their direct and/or indirect zinc chelating ability? Loris Zamai
8 [GO] 2022―Nov―17 Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2 Wern Hann Ng, Patrick Chun Hean Tang, Suresh Mahalingam, Xiang Liu
9 [GO] 2022―Mar―29 Niclosamide - a promising treatment for COVID-19 Shivani Singh, Anne Weiss, James Goodman, Marie Fisk, Spoorthy Kulkarni, Ing Lu, Joanna Gray, Rona Smith, Morten Sommer, Joseph Cheriyan
10 [GO] 2022―Feb―19 Hypothesis: How far are we from predicting multi-drug interactions during treatment for COVID-19 infection? Benjamin Lozano, Javier Santibañez, Nicolás Severino, Cristina Saldias, Magdalena Vera, Jaime Retamal, Soledad Torres, Nelson P. Barrera
11 [GO] 2021―Oct―11 Pyroptosis targeting via mitochondria: An educated guess to innovate COVID-19 therapies Aarti Singh, Daniela Strobbe, Michelangelo Campanella
12 [GO] 2021―Jul―31 Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine Loris Zamai, Marco B. L. Rocchi
13 [GO] 2021―Jul―08 Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019 Saravanan Subramaniam, Wolfram Ruf, Markus Bosmann
14 [GO] 2021―Jun―15 Thromboinflammation in COVID-19: The Clot Thickens Raayma Iffah, Felicity N. E. Gavins
15 [GO] 2021―Jun―04 The Impact of COVID-19 on Pregnancy and Therapeutic Drug Development Allyah Abbas-Hanif, Homira Rezai, S. Faraz Ahmed, Asif Ahmed
16 [GO] 2021―Jun―01 Therapeutic potential of mega-dose vitamin C to reverse organ dysfunction in sepsis and COVID-19 Clive N. May, Rinaldo Bellomo, Yugeesh R. Lankadeva
17 [GO] 2021―May―08 Therapeutic strategies to fight COVID-19: Which is the status artis ? Cristina Scavone, Annamaria Mascolo, Concetta Rafaniello, Liberata Sportiello, Ugo Trama, Alice Zoccoli, Francesca Futura Bernardi, Giorgio Racagni, Liberato Berrino, Giuseppe Castaldo, Enrico Coscioni, Francesco Rossi, Annalisa Capuano
18 [GO] 2021―Apr―07 Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro Sebastian Schloer, Linda Brunotte, Angeles Mecate-Zambrano, Shuyu Zheng, Jing Tang, Stephan Ludwig, Ursula Rescher
19 [GO] 2021―Mar―26 Dual inhibition of CB 1 R and iNOS as a potential novel approach to the pharmacological management of acute and long COVID-19 Resat Cinar, Malliga R. Iyer, George Kunos
20 [GO] 2021―Jan―29 NEUROLOGICAL RISKS AND BENEFITS OF CYTOKINE-BASED TREATMENTS IN COVID-19: FROM PRECLINICAL TO CLINICAL EVIDENCE Giuseppe Pignataro, Mauro Cataldi, Maurizio Taglialatela
21 [GO] 2021―Jan―06 COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31 Francesca Levi-Schaffer, Ario Marco
22 [GO] 2020―Dec―12 Can the hyperthermia-mediated Heat Shock Factor (HSF) /Heat Shock Protein (HSP) 70 pathway dampen the cytokine storm during SARS-CoV-2 infection? Cédric Rébé, François Ghiringhelli, Carmen Garrido
23 [GO] 2020―Dec―07 Low bioavailability hinders drug discovery against COVID-19, guided by in silico docking Priyankar Dey
24 [GO] 2020―Nov―03 Update on animal models for COVID-19 research Simon J. Cleary, Mélia Magnen, Mark R. Looney, Clive P. Page
25 [GO] 2020―Oct―30 Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations Julia A. Tree, Jeremy E. Turnbull, Karen R. Buttigieg, Michael J. Elmore, Naomi Coombes, John Hogwood, Courtney J. Mycroft-West, Marcelo A. Lima, Mark A. Skidmore, Richard Karlsson, Yen-Hsi Chen, Yang Zhang, Cosma Mirella Spalluto, Karl J. Staples, Edwin A. Yates, Elaine Gray, Dave Singh, Tom Wilkinson, Clive P. Page, Miles W. Carroll
26 [GO] 2020―Sep―02 Databases for the Targeted COVID-19 Therapeutics Yunxia Wang, Fengcheng Li, Ying Zhang, Ying Zhou, Ying Tan, Yuzong Chen, Feng Zhu
27 [GO] 2020―Aug―12 Anti-inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H 2 S-donors in COVID-19 therapy Valentina Citi, Alma Martelli, Vincenzo Brancaleone, Simone Brogi, Gabriel Gojon, Rosangela Montanaro, Guillermo Morales, Lara Testai, Vincenzo Calderone
28 [GO] 2020―Aug―10 The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: lessons for drug repurposing Ilaria Bertocchi, Federica Foglietta, Debora Collotta, Carola Eva, Vincenzo Brancaleone, Christoph Thiemermann, Massimo Collino
29 [GO] 2020―Jul―23 Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19 Calum T. Robb, Marie Goepp, Adriano G. Rossi, Chengcan Yao
30 [GO] 2020―Jul―22 Sex-Related Differences in COVID-19 Lethality Claudia Penna, Valentina Mercurio, Carlo G. Tocchetti, Pasquale Pagliaro
31 [GO] 2020―Jul―18 Safety perspectives on presently considered drugs for the treatment of COVID-19 Sophie L. Penman, Robyn T. Kiy, Rebecca L. Jensen, Christopher Beoku-Betts, Ana Alfirevic, David Back, Saye H. Khoo, Andrew Owen, Munir Pirmohamed, B. Kevin Park, Xiaoli Meng, Christopher E. Goldring, Amy E. Chadwick
32 [GO] 2020―Jul―16 Targeting zinc metalloenzymes in COVID-19 Urszula Doboszewska, Piotr Wlaź, Gabriel Nowak, Katarzyna Młyniec
33 [GO] 2020―Jul―09 Tackling COVID-19 infection through complement-targeted immunotherapy Sonata Jodele, Jörg Köhl
34 [GO] 2020―Jul―08 Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19? Krishna Sriram, Paul A. Insel
35 [GO] 2020―Jun―30 The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question Giuseppe Cirino, Amrita Ahluwalia
36 [GO] 2020―Jun―20 Novel Approach for Low-Dose Pulmonary Delivery of Hydroxychloroquine in COVID-19 Safa C. Fassihi, Neel R. Nabar, Reza Fassihi
37 [GO] 2020―Jun―20 Statins: Could an old friend help the fight against COVID-19? Raul R. Rodrigues-Diez, Antonio Tejera-Muñoz, Laura Marquez-Exposito, Sandra Rayego-Mateos, Laura Santos Sanchez, Vanessa Marchant, Lucía Tejedor Santamaria, Adrian M. Ramos, Alberto Ortiz, Jesus Egido, Marta Ruiz-Ortega
38 [GO] 2020―Jun―18 Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19? Lirlândia P. Sousa, Vanessa Pinho, Mauro M. Teixeira
39 [GO] 2020―Jun―10 The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter Giuseppe Esposito, Marcella Pesce, Luisa Seguella, Walter Sanseverino, Jie Lu, Chiara Corpetti, Giovanni Sarnelli
40 [GO] 2020―Jun―04 A lesson from a saboteur: high molecular weight kininogen (HMWK) impact in COVID-19 Chiara Colarusso, Michela Terlizzi, Aldo Pinto, Rosalinda Sorrentino
41 [GO] 2020―May―28 Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology Simon J. Cleary, Simon C. Pitchford, Richard T. Amison, Robert Carrington, C. Lorena Robaina Cabrera, Mélia Magnen, Mark R. Looney, Elaine Gray, Clive P. Page
42 [GO] 2020―May―22 A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19) Francesco Di Virgilio, Yong Tang, Alba Clara Sarti, Marco Rossato
43 [GO] 2020―May―22 Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS? Nicola Curtin, Krisztián Bányai, James Thaventhiran, John Le Quesne, Zsuzsanna Helyes, Péter Bai
44 [GO] 2020―May―22 The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS). Faleh Tamimi, Mohammad Abusamak, Bindu Akkanti, Zheng Chen, Seung-Hee Yoo, Harry Karmouty-Quintana
45 [GO] 2020―May―19 Lung tissue distribution of drugs as a key factor for COVID-19 treatment Yan Wang, Lei Chen
46 [GO] 2020―May―05 Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2 Hong Zhou, Yan Fang, Tao Xu, Wei-Jian Ni, Ai-Zong Shen, Xiao-Ming Meng
47 [GO] 2020―May―02 A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29 S.P.H. Alexander, J. Armstrong, A.P. Davenport, J. Davies, E. Faccenda, S.D. Harding, F. Levi-Schaffer, J.J. Maguire, A.J. Pawson, C. Southan, M.J. Spedding
48 [GO] 2020―Apr―29 Inhaled Nitric Oxide and COVID-19 Louis J. Ignarro
49 [GO] 2020―Apr―25 A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance Krishna Sriram, Paul A. Insel
50 [GO] 2020―Apr―24 Current pharmacological treatments for COVID-19: what’s next? Cristina Scavone, Simona Brusco, Michele Bertini, Liberata Sportiello, Concetta Rafaniello, Alice Zoccoli, Liberato Berrino, Giorgio Racagni, Francesco Rossi, Annalisa Capuano
 [1] 

50 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec